Chabiotech Co Ltd

Chabiotech's capital structure is characterized by a high debt-to-equity ratio of 3.07, indicating a significant reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.67, suggesting that it may face challenges in meeting its short-term obligations. The price-to-book ratio of 3.69 indicates that the market values the company at a premium to its book value, but this is not supported by positive earnings or cash flows.

In terms of profitability, Chabiotech is currently unprofitable, with a net loss of -109,876,117,780 KRW and an operating loss of -99,571,795,580 KRW. The return on equity is -0.3607, and the return on assets is -0.0431, both of which are negative and significantly below the industry median for profitable biotechnology firms. The company's operating cash flow is negative at -72,522,501,540 KRW, and its free cash flow is also negative at -242,553,733,270 KRW, indicating that it is not generating sufficient cash from operations to sustain its activities.

Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data, but the biotechnology industry is typically characterized by high R&D intensity and long development cycles. Chabiotech's financials suggest a focus on R&D and capital expenditures, with a capital expenditure of -152,066,302,190 KRW, which is a significant outflow. The company's revenue of 1,268,253,668,580 KRW is derived from its biotechnology activities, but the lack of segment-specific data limits the ability to assess geographic or product diversification.

The company's growth trajectory is uncertain, with no specific outlook provided for the current or next fiscal year. The negative operating and net income, combined with negative cash flows, suggest that the company is not currently in a growth phase and may require additional financing to continue operations. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the key flag of negative net cash after subtracting total debt highlights the company's financial vulnerability.

Recent events and filings do not provide specific details on the company's strategic initiatives or financial developments. The last actual EPS was 228.02 KRW, and the last actual revenue was 488,600,000,000 KRW, but these figures do not indicate a clear trend or improvement in the company's financial performance. The company's market price of 14,270 KRW and market cap of 1,124,933,310,690 KRW suggest that the market has limited confidence in the company's ability to generate positive returns in the near term.